QIAGEN's QIAstat-Dx Rise Receives FDA Clearance, Boosts Diagnostics Portfolio and Stock Potential

QIAGEN's QIAstat-Dx Rise system, cleared by the FDA, offers enhanced throughput and ease of use for hospitals and reference laboratories. The system can run up to 160 tests per day and is already available in over 100 countries with over 4,600 instruments placed globally. QIAGEN plans to add gastrointestinal panels to the system in the coming months. The syndromic multiplex diagnostics market is expected to grow at a CAGR of 3.9% through 2030, favoring QIAGEN's prospects.